Birgit Harbeck
Peter Kropp
Ilonka Kreitschmann-Andermahr- 1III. Department of Medicine, University Medical Center Hamburg-Eppendorf, Hamburg, Germany
- 2Medizinisches Versorgungszentrum (MVZ) Amedes Experts, Endocrinology, Hamburg, Germany
- 3Institute of Medical Psychology and Medical Sociology, University of Rostock, Rostock, Germany
- 4Department of Neurosurgery and Spine Surgery, University Hospital Essen, Essen, Germany
Patients with adrenal insufficiency (AI) are treated with conventional or modified-release glucocorticoid (GC) replacement therapy (GRT). Although current GRT regimens aim to mimic the physiological circadian pattern of cortisol secretion, temporary phases of hypo- and hypercortisolism are common. There is good evidence that prolonged phases of hypo- or hypercortisolism are associated with impaired cognitive functioning. However, little is known about cognitive functioning in patients with AI regarding the effects of dosage and duration of glucocorticoid replacement therapy. There is also little data available comparing the effects of GC therapy on patients with primary and secondary forms of AI as well as with respect to different formulas. This Mini-Review gives an overview of the current studies on GRT for primary and secondary AI and their impact on cognition. Strengths and weaknesses of the studies and their Implications for clinical daily routine are discussed with a special emphasis on practical considerations for the treating endocrinologist.
1 Introduction
Adrenal insufficiency (AI) describes a life-threatening condition caused by the inability of the adrenal glands to produce adequate amounts of cortisol. Adrenal glucocorticoid hormones are pivotal for maintenance of homeostasis and stress adaptation. AI can be divided into primary adrenal insufficiency (PAI), occurring at the level of the adrenals, secondary adrenal insufficiency (SAI), caused by dysfunction of the pituitary gland and tertiary adrenal insufficiency (TAI) which develops as a consequence of exogenous steroid treatment.
In Western countries PAI is a rare disease with a prevalence of 93 to 126 cases per million (1). It is mainly caused by an autoimmune disorder, called Addisons`s disease, which is responsible for > 80% of PAI cases. SAI is mainly caused by pituitary adenomas or other pituitary pathologies, including causes such as posttraumatic or radiation-induced pituitary dysfunction (2). The overall prevalence of SAI is about 455 cases per million (1, 3). TAI is the most common type of AI and usually caused by sudden withdrawal from long-term exogenous steroid use in patients, e.g., treated for inflammatory disorders. AI of any origin leads to a lack of endogenous glucocorticoids (GC) with typical clinical symptoms: unintentional weight loss, hypotension, fatigue, hyponatremia, muscle and abdominal pain (4). If untreated, symptoms can culminate to a potentially lethal event called adrenal crisis (5).
Patients with AI require life-long glucocorticoid replacement therapy (GRT). State of the art is treatment with hydrocortisone (15-25 mg HC), given in two or three doses daily with the highest dose in the morning (6). Although aiming to mimic the physiological pattern of cortisol release as closely as possible by splitting the total daily dose into 2-3 portions, such a regimen is still unphysiological and cannot prevent a temporary hyper- and hypocortisolism (7) contributing to morbidity and reduced life expectancy of the afflicted patients (8–11). Cardiovascular disease is the main cause of death in AI patients (12), with comorbidities largely accounting for the increase in mortality. GC replacement therapy itself (in particular HC doses > 20 mg/d) adversely affects some of the well-known risk factors for cardiovascular disease (CVD), for example, obesity, hypertension, diabetes, and hyper- lipoproteinemia (8, 13, 14). Temporary hypocortisolism may lead to subsequent increase of inflammatory markers being involved in atherosclerosis such as Interleukin 1 (IL-1), Interleukin 6 (IL-6), and tumor-necrosis factor (TNF) (15–18).
Moreover, health-related quality of life (HRQoL) is consistently reduced in patients with AI, despite adequate GRT (19, 20). Given the brain’s density of mineralocorticoid (MC) and glucocorticoid (GC) receptors and their profound role in neuropsychological functioning (21), it seems plausible that the inadequate cortisol homeostasis in AI contributes to reduced QoL and might also negatively influence cognition in the afflicted patients. An inverted-U-shaped pattern between circulating glucocorticoids and cognitive function has been repeatedly demonstrated (22, 23), implying that too high – as in Cushing’s syndrome (CS) – but also too low - as in underreplaced or unphysiologically replaced AI – cortisol levels negatively affect i.e. memory acquisition and retention (24–26). On a similar note, already the acute modulation of human cortisol levels by inhibition of cortisol production has been shown to impair memory, with the effect being completely reversed by subsequent administration of HC (27, 28).
In patients with active Cushing’s disease (CD) or CS, the literature gives evidence for impairments in all neuropsychological domains, most consistently concerning memory and visuo-spatial processing (for an overview see 29). Interestingly, short- and long-term remission of the disease are not generally associated with a normalization of cognitive function (for an overview see 29), perhaps not only owing to the effects of former glucocorticoid excess on the brain, but also to unphysiological replacement regimens in patients with cured hypercortisolism and consecutive SAI. Additional, preliminary evidence that hypocortisolism could impede neuropsychological functioning stems from patients recovered from aneurysmal subarachnoid hemorrhage (SAH) in whom low basal cortisol levels were the first and often only predictors for impairments in several QoL domains assessing psychological aspects of well-being and depression, whereas physical aspects of QoL were predicted mainly be neurological recovery from the SAH (30).
Modified-release hydrocortisone (MR-HC) preparations, introduced in recent years to avoid rapid rises in cortisol levels and to mimic the circadian rhythm of cortisol more physiologically (31) have already been shown to exhibit positive effects on metabolic profiles and cardiovascular parameters (32). It is conceivable that they may exhibit also favorable effects on cognitive function in patients with AI. Against the background of the increasing availability of more physiological HC replacement regimens, it is the aim of the present mini-review to present the reader with an overview on the published literature on cognitive dysfunction in patients with AI on GRT. Emphasis will be placed on practical considerations for the treating endocrinologist and the identification of potential research gaps and open questions in the field.
2 Methods
This Mini-Review aims to highlight previous studies on GRT and cognitive function. To this end, we conducted a systematic search through PubMed for all articles until December 31, 2022. We searched for any combination of the terms “glucocorticoid replacement therapy/glucocorticoids/hydrocortisone” or “adrenal insufficiency”/”Addison” with catchphrases relating to “cognition”, “cognitive”, “cognitive function”, “neurocognitive”, “neuropsychological”, “memory”, “executive function”, “impaired cognitive function”, “cognitive dysfunction”, “cognitive disorder”. All articles reporting original data and review articles on this topic in peer reviewed journals were screened for inclusion into the present review. We also searched the reference lists of articles identified by this search strategy to prevent overlooking relevant articles. Studies reporting data in patients with known neurological disorders or children were excluded.
3 Results
From our literature search, 11 studies were identified to be included in the present Mini-Review. Seven studies with a total of 235 patients and 248 healthy controls investigated potential neuropsychological impairment in patients with PAI (26, 33–38). In most of the studies an extensive neuropsychological test battery, administered in person, was used, whereas one study (35) relied on a self-report questionnaire on cognition and a further one on telephone-administered cognitive testing (37). In sum, the studies found none to only mild cognitive deficits in the investigated patients regarding subscales of memory (26, 33, 34, 37), attention (38) and executive functions (26).
Interestingly, the lack of gross objectifiable impairment was accompanied in some studies by a high incidence of self-experienced problems, i.e., in executive function, memory, and impaired QoL (26, 33, 35). In two of the studies, primarily designed to investigate the impact of sleep disturbances of PAI patients on neuropsychological functioning and cognition, sleep disturbances in PAI patients were uncovered by means of self-rating questionnaires. The studies’ authors postulated that the mild impairments in verbal learning and memory seen in the patients with PAI were due to their disrupted sleep patterns (34, 35), whereas another one interpreted impaired attention in PAI patients as a neuroglycopenic feature of Addison’s disease (38).
Two further studies included not only PAI but also SAI patients as well as healthy controls. The AI patients were investigated in in-group comparisons with respect to GRT dose (> 20 mg/die) and etiology (PAI vs. SAI) and against healthy matched controls. The two studies, investigating different patient groups, yield contradictory results in terms of PAI/SAI comparison and dosing regimen: one found PAI patients to perform better on tasks assessing intellectual abilities and executive function (39) whereas the other was not able to uncover differences between the two patient groups (40), using the same test battery.
A further difference concerned cognitive functioning between patients on low- versus high-dose HC replacement, with Blacha finding a negative effect of high-dose GRT on several cognitive domains while Krekeler did not (39, 40). While the number of patients investigated in the studies is not so low, the studies did not account for age or psychiatric morbidity as potential confounders of their results.
The last three studies in the field do not investigate AI patients in comparison to healthy controls but aimed to study whether different GRT regimens (41, 42) or disease duration (operationalized as duration of HC replacement, 43) impacted on cognition in patients with PAI and/or SAI. The largest of the three investigated SAI patients in a double-blind cross-over design after 10 weeks on physiological high-dose versus low-dose GRT with an extensive neuropsychological test battery (41). Additionally, serum cortisol levels were obtained in order to confirm differences between high- and low dose regimens. In this well-designed study, no differences in cognitive performance between the two dose regimens were found. The other two studies investigate a sample of 14 PAI/SAI patients, once under the condition of a nocturnal HC infusion (42) and once with respect to duration of HC replacement (43). In both no significant differences in cognition were found between the respective study conditions. A detailed table which lists the studies described here, can be found as supplemental material.
4 Discussion
Although an important topic, only a few trials about cognitive function in AI are available. Here, we review a total of 11 studies that reported cognitive functioning in patients with PAI and or SAI in comparison to healthy controls or under various HC replacement conditions. Cognitive impairment in AI patients was in general only mild or non-existent. If present, it concerned attention, executive functioning and memory domains and was attributed by some authors to AI-associated features such as sleep disturbances or impaired hypoglycemic control (34, 35, 38). On the other hand, in some studies, AI patients performed as well as their matched controls. In stark contrast to the overall mild objectifiable deficits, the largest of the studies reviewed here and two further studies found a high prevalence of self-experienced impairments concerning cognition and executive functioning (26, 33, 35).
Thus, the thin, current body of evidence does not reflect the pathophysiological hypotheses outlined in the introduction of this paper, which may be explained by the limitations of the studies in the field. First, some were published by a limited number of research groups. Two were based on one patient group investigated under different conditions (42, 43), from others it cannot be excluded that patients of former studies had been included repeatedly, thus conducting subsample analyses. Further conceptual weaknesses include a selection bias, especially in those studies investigating patients with PAI and SAI (39, 40) or the study by Van´t Westeinde et al. who included patients with a young median age and controls with exceptionally high neuropsychological test scores (33). Furthermore, the number of investigated patients was, in general, rather low, ranging from 10 – 67 patients, the latter constituting an exceptionally large sample. To confound matters further, the construct of “cognitive function” has been operationalized in the literature by different neuropsychological test batteries administered in person, at best (26, 33, 34, 36, 39–43), by telephone (37) or self-rating questionnaires (35). Moreover, virtually none of the studies controlled for age or internal medicine comorbidities, which might also have an influence on cognitive performance, and some did not control for psychiatric comorbidities such as anxiety or depression. The latter is important, though, as it is well researched that depression as well as anxiety may influence cognitive functioning to a considerable extent (44, 45). Last, but not least, the included patients had largely different disease durations and GRT regimens. This might be, however, a potentially minor concern, as the current study situation does not uncover a consistent influence of disease duration or different GRT dosing regimens, including MR-HC, on cognition. Similar concerns about the study situation have also been voiced by Ramos-Levi (46).
Taken in sum, the current body of evidence seems at first sight to be a clinical conundrum for the practicing endocrinologist. From the authors’ point of view, the most important take-home message is that no gross objectifiable neuropsychological impairment in patients with replaced AI has been proven so far and that different dosing regimens do not seem to impact significantly on cognition. This is an important point since from our experience patients tend to associate higher HC doses with a better efficacy, while the contrary holds true for metabolic, cardiovascular, bone parameters (47–50) and even QoL (47, 51, 52). Additionally, it is important to keep in mind that self-experienced cognitive impairment in patients with AI is hardly reflected in objective measurements. From a practical point of view, it seems advisable to counsel patients on this discrepancy and reassure them that their illness and its treatment is, in the great majority cases, not associated with cognitive dysfunction per se. Secondly, AI patients voicing severe neuropsychological complaints should be screened for depression and treated accordingly, as cognitive impairment may be caused or amplified by psychiatric comorbidity. In those patients, in whom clinically relevant depression is excluded or adequately treated and in whom cognitive disorders relevant to everyday life are present, neurological referral is advisable.
From a scientific point of view, large-scale studies, controlled for age, psychiatric and internal medicine comorbidities and GRT regimens will certainly expand our knowledge in the field. Additionally, the discrepancy between subjective and objectifiable cognitive impairment in AI patients deserves further research, especially against the background of designing therapeutic interventions. As large patient numbers are required to conduct discriminative statistics and interpret the results, the neuropsychological test batteries should include robust tests with no or little interrater variability paving the way for multicenter study designs that will allow to investigate enough patients with this rare disease.
Author contributions
BH: concept/design, data analysis/interpretation, drafting article, and approval of article. PK: critical revision of article and approval of article. IK-A: concept/design, data analysis/interpretation, drafting article, and approval of article. All authors contributed to the article and approved the submitted version.
Conflict of interest
Author BH is employed by the company Medizinisches Versorgungszentrum (MVZ) Amedes Experts.
The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Publisher’s note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.
Supplementary material
The Supplementary Material for this article can be found online at: https://www.frontiersin.org/articles/10.3389/fendo.2023.1153595/full#supplementary-material
References
1. Meyer G, Badenhoop K, Linder T. Addison’s disease with polyglandular autoimmunity carries a more than 2·5-fold risk for adrenal crises: German health insurance data 2010–2013. Clin Endocrinol (2016) 85:347–53. doi: 10.1111/cen.13043
2. Pekic S, Popovic V. Diagnosis of endocrine disease: expanding the cause of hypopituitarism. Eur J Endocrinol (2017) 176:R269–82. doi: 10.1530/EJE-16-1065
3. Quinkler M, Beuschlein F, Hahner S, Meyer G, Schoff C, Stalla GK. Nebennierenrinden-insuffizienz - lebensbedrohliche erkrankung mit vielfältigen ursachen. Deutsches Ärzteblatt Int (2013) 110:882–88. doi: 10.3238/arztebl.2013.0882
4. Husebye ES, Pearce SH, Krone NP, Kämpe O. Adrenal insufficiency. Lancet (2021) 397:613–29. doi: 10.1016/S0140-6736(21)00136-7
5. Hahner S. Acute adrenal crisis and mortality in adrenal insufficiency: still a concern in 2018! Annales d’Endocrinologie (2018) 79:164–66. doi: 10.1016/j.ando.2018.04.015
6. Bornstein SR, Allolio B, Arlt W, Barthel A, Don-Wauchope A, Hammer GD, et al. Diagnosis and treatment of primary adrenal insufficiency: An endocrine society clinical practice guideline. J Clin Endocrinol Metab (2016) 101:364–89. doi: 10.1210/jc.2015-1710
7. Chan S, Debono M. Review: replication of cortisol circadian rhythm: new advances in hydrocortisone replacement therapy. Therap Adv Endocrinol Metab (2010) 1:129–38. doi: 10.1177/2042018810380214
8. Rahvar AH, Haas CS, Danneberg S, Harbeck B. Increased cardiovascular risk in patients with adrenal insufficiency: A short review. Biomed Res Int (2017) 2017:1–5. doi: 10.1155/2017/3691913
9. Erichsen MM, Løva°Cs K, Fougner KJ, Svartberg J, Hauge ER, Bollerslev J, et al. Normal overall mortality rate in addison’s disease, but young patients are at risk of premature death. Eur J Endocrinol (2009) 160:233–37. doi: 10.1530/EJE-08-0550
10. Tomlinson JW, Holden N, Hills RK, Wheatley K, Clayton RN, Bates AS, et al. Association between premature mortality and hypopituitarism. Lancet (2001) 357:425–31. doi: 10.1016/S0140-6736(00)04006-X
11. Falhammar H, Frisén L, Norrby C, Hirschberg AL, Almqvist C, Nordenskjöld A, et al. Increased mortality in patients with congenital adrenal hyperplasia due to 21-hydroxylase deficiency. J Clin Endocrinol Metab (2014) 99:E2715–21. doi: 10.1210/jc.2014-2957
12. Ngaosuwan K, Johnston DG, Godsland IF, Cox J, Majeed A, Quint JK, et al. Cardivoascular disease in patients with primary and secondary adrenal insufficiendy and the role of comorbidities. J Clin Endocrinol Metab (2021) 106:1284–93. doi: 10.1210/clinem/dgab063
13. Filipsson H, Monson JP, Koltowska-Häggström M, Mattsson A, Johannsson G. The impact of glucocorticoid replacement regimens on metabolic outcome and comorbidity in hypopituitary patients. J Clin Endocrinol Metab (2006) 91:3954–61. doi: 10.1210/jc.2006-0524
14. Debono M, Ross RJ, Newell-Price J. Inadequacies of glucocorticoid replacement and improvements by physiological circadian therapy. Eur J Endocrinol (2009) 160:719–29. doi: 10.1530/EJE-08-0874
15. Papanicolaou DA, Tsigos C, Oldfield EH, Chrousos GP. Acute glucocorticoid deficiency is associated with plasma elevations of interleukin-6: Does the latter participate in the symptomatology of the steroid withdrawal syndrome and adrenal insufficiency? J Clin Endocrinol Metab (1998) 81:2303–06. doi: 10.1210/jcem.81.6.8964868
16. Mastorakos G, Paltoglou G, Greene M, Ilias I, Papamichalopoulos A, Dimopoulos S, et al. Inappropriately normal plasma ACTH and cortisol concentrations in the face of increased circulating interleukin-6 concentration in exercise in patients with sarcoidosis. Stress (2013) 16:202–10. doi: 10.3109/10253890.2012.715221
17. Rahvar AH, Riesel M, Graft T, Harbeck B. Adrenal insufficiency treated with conventional hydrocortisone leads to elevated levels of interleukin-6: a pilot study. Endocrine (2019) 64:727–29. doi: 10.1007/s12020-019-01956-3
18. Vicenová B, Vopálensky V, Burysek L, Pospisek M. Emerging role of interleukin-1 in cardiovascular diseases. Physiol Res (2009) 58:481–98. doi: 10.33549/physiolres.931673
19. Esposito D, Falorni A, Johannsson G. Editorial: Primary adrenal insufficiency- quality of life and long-term outcome with current treatment strategies. Front Endocrinol (Lausanne) (2022) 13:886762. doi: 10.3389/fendo.2022.886762
20. Bancos I, Hahner S, Tomlinson J, Arlt W. Diagnosis and management of adrenal insufficiency. Lancet Diabetes Endocrinol (2015) 3:216–26. doi: 10.1016/S2213-8587(14)70142-1
21. de Kloet ER. From receptor balance to rational glucocorticoid therapy. Endocrinology (2014) 155:2754–69. doi: 10.1210/en.2014-1048
22. Lupien SJ, Gillin CJ, Hauger RL. Working memory is more sensitive than declarative memory to the acute effects of corticosteroids: A dose-response study in humans. Behav Neurosci (1999) 113:420–30. doi: 10.1037/0735-7044.113.3.420
23. Joels M. Corticosteroid effects in the brain: U-shape it. Trends Pharmacol Sci (2006) 27:244–50. doi: 10.1016/j.tips.2006.03.007
24. Piasecka M, Papakokkinou E, Valassi E, Santos A, Webb SM, de Vries F, et al. Psychiatric and neurocognitive consequences of endogenous hypercortisolism. J Intern Med (2020) 288:168–82. doi: 10.1111/joim.13056
25. Pivonello R, Simeoli C, De Martino MC, Cozzolino A, De Leo M, Iacuaniello D, et al. Neuropsychiatric disorders in cushing's syndrome. Front Neurosci (2015) 9:129. doi: 10.3389/fnins.2015.00129
26. Tiemensma J, Andela CD, Biermasz NR, Romijn JA, Pereira AM. Mild cognitive deficits in patients with primary adrenal insufficiency. Psychoneuroendocrinology (2016) 63:170–7. doi: 10.1016/j.psyneuen.2015.09.029
27. Lupien SJ, Wilkinson CW, Brière S, Ménard C, Ng Ying Kin NM, Nair NP. The modulatory effects of corticosteroids on cognition: studies in young human populations. Psychoneuroendocrinology (2002) 27:401–16. doi: 10.1016/s0306-4530(01)00061-0
28. Lupien SJ, Wilkinson CW, Brière S, Ng Ying Kin NM, Meaney MJ, Nair NP. Acute modulation of aged human memory by pharmacological manipulation of glucocorticoids. J Clin Endocrinol Metab (2002) 87:3798–807. doi: 10.1210/jcem.87.8.8760
29. Siegel S, Kirstein CF, Grzywotz A, Hütter BO, Wrede KH, Kuhna V, et al. Neuropsychological functioning in patients with cushing's disease and cushing's syndrome. Exp Clin Endocrinol Diabetes (2021) 129:194–202. doi: 10.1055/a-1247-4651
30. Kreitschmann-Andermahr I, Poll E, Hutter BO, Reineke A, Kristes S, Gilsbach JM, et al. Quality of life and psychiatric sequelae following aneurysmal subarachnoid haemorrhage: Does neuroendocrine dysfunction play a role? Clin Endocrinol (Oxf) (2007) 66:833–37. doi: 10.1111/j.1365-2265.2007.02821.x
31. Johannsson G, Nilsson AG, Bergthorsdottir R, Burman P, Dahlqvist P, Ekman B, et al. Improved cortisol exposure-time profile and outcome in patients with adrenal insufficiency: A prospective randomized trial of a novel hydrocortisone dual-release formulation. J Clin Endocrinol Metab (2012) 97:473–81. doi: 10.1210/jc.2011-1926
32. Mongiol LM, Condorell RA, Barbagallo F, La Vignera S, Calogero AE. Dual-release hydrocortisone for treatment of adrenal insufficiency: A systematic review. Endocrine (2020) 67:507–15. doi: 10.1007/s12020-020-02187-7
33. Van´t Westeinde A, Ström S, Hirvikosk T, Dahlqvist P, Wahlberg J, Gezellus A, et al. Young adult Swedish patients with autoimmune addison´s disease report difficulties with executive functions in daily life despite overall good cognitive performance. Psychoneuroendocrinology (2022) 140:105714. doi: 10.1016/j.psyneuen.2022.105714
34. Henry M, Ross IL, Wolf PSA, Thomas KGF. Impaired quality and efficiency of sleep impairs cognitive functioning in addison´s disease. Psychoneuroendocrinology (2017) 78:237–45. doi: 10.1016/j.psyneuen.2017.02.004
35. Henry M, Wolf PS, Ross IL, Thomas KG. Poor quality of life, depressed mood, and memory impairment may be mediated by sleep disruption in patients with addison’s disease. Physiol Behav (2015) 151:379–85. doi: 10.1016/j.physbeh.2015.08.011
36. Schultebraucks K, Wingenfeld K, Heimes J, Quinkler M, Otte C. Cognitive function in patients with primary adrenal insufficiency (Addison´s disease). Psychoneuroendocrinology (2015) 55:1–7. doi: 10.1016/j.psyneuen.2015.01.025
37. Henry M, Thomas KG, Ross IL. Episodic memory impairment in addison´s disease: results from a telephone cognitive assessment. Metab Brain Dis (2014) 29:421–30. doi: 10.1007/s11011-014-9511-x
38. Klement J, Hubold C, Cords H, Oltmanns KM, Hallschmid M, Born J, et al. High-calorie glucose-rich food attenuates neuroglycopenic symptoms in patients with addison´s disease. J Clin Endocrinol Metab (2010) 95:522–28. doi: 10.1210/jc.2009-1752
39. Krekeler C, Kropp P, Blacha AK, Rahvar AH, Harbeck B. Dual-release hydrocortisone and its benefits on cognitive function and quality of sleep. Endocrine (2021) 72:223–33. doi: 10.1007/s12020-020-02552-6
40. Blacha AK, Rahvar AH, Flitsch J, van de Loo I, Kropp P, Harbeck B. Impaired attention in patients with adrenal insufficiency-impact of unphysiological therapy. Steroids (2021) 167:108788. doi: 10.1016/j.steroids.2020.108788
41. Werumeus Buning J, Brummelman P, Koerts J, Dullaart RP, van den Berg G, van der Klauw MM, et al. The effects of two different doses of hydrocortisone on cognition in patients with secondary adrenal insufficiency-results from a randomized controlled trial. Psychoneuroendocrinology (2015) 55:36–47. doi: 10.1016/j.psyneuen.2015.02.001
42. Harbeck B, Kropp P, Mönig H. Effects of short-term nocturnal cortisol replacement on cognitive function and quality of life in patients with primary or secondary adrenal insufficiency: A pilot study. Appl Psychophysiol Biofeedback (2009) 34:113–19. doi: 10.1007/s10484-009-9082-5
43. Harbeck B, Danneberg S, Rahvar AH, Haas CS, Lehnert H, Kropp P, et al. Exploring the impact of short-and long-term hydrocortisone replacement on cognitive function, quality of life and catecholamine secretion: A pilot study. Appl Psychophysiol Biofeedback (2016) 41:341–47. doi: 10.1007/s10484-016-9338-9
44. Rock PL, Roiser JP, Riedel WJ, Blackwell AD. Cognitive impairment in depression: A systematic review and meta-analysis. Psychol Med (2014) 44:2029–40. doi: 10.1017/S0033291713002535
45. Tetzner J, Schuth M. Anxiety in late adulthood: Associations with gender, education, and physical and cognitive functioning. Psychol Aging (2016) 31:532–44. doi: 10.1037/pag0000108
46. Ramos-Leví AM, Canada E, Matias-Guiu JA. Cognitive dysfunction in patients with primary adrenal insufficiency: A systematic review. Appl Neuropsychol Adult (2022) 29:1–12. doi: 10.1080/23279095.2022.2090256
47. Danilowicz K, Bruno OD, Manavela M, Gomez RM, Barkan A. Correction of cortisol overreplacement ameliorates morbidities in patients with hypopituitarism: A pilot study. Pituitary (2008) 11:279–85. doi: 10.1007/s11102-008-0126-2
48. Giordano R, Marzotti S, Balbo M, Romagnoli S, Marinazzo E, Berardelli R, et al. Metabolic and cardiovascular profile in patients with addison´s disease under conventional glucocorticoid replacement. J Endocrinol Invest (2009) 32:917–23. doi: 10.3275/6437
49. Johannsson G, Ragnarsson O. Cardiovascular and metabolic impact of glucocorticoid replacement therapy. Front Horm Res (2014) 43:33–44. doi: 10.1159/000360556
50. Schulz J, Frey KR, Cooper MS, Zopf K, Ventz M, Diederich S, et al. Reduction in daily hydrocortisone dose improves bone health in primary adrenal insufficiency. Eur J Endocrinol (2016) 174:531–38. doi: 10.1530/EJE-15-1096
51. Tiemensma J, Andela CD, Kaptein AA, Romijn JA, van der Mast RC, Biermasz NR, et al. Psychological morbidity and impaired quality of life in patients with stable treatment for primary adrenal insufficiency: Cross-sectional study and review of the literature. Eur J Endocrinol (2014) 171:171–82. doi: 10.1530/EJE-14-0023
Keywords: adrenal insufficiency, glucocorticoids, replacement therapy, cognition, sleep
Citation: Harbeck B, Kropp P and Kreitschmann-Andermahr I (2023) Glucocorticoid replacement therapy for primary and secondary adrenal insufficiency and their impact on cognition. Front. Endocrinol. 14:1153595. doi: 10.3389/fendo.2023.1153595
Received: 29 January 2023; Accepted: 07 March 2023;
Published: 17 March 2023.
Edited by:
Ian Ross, University of Cape Town, South AfricaReviewed by:
Valeria Hasenmajer, Department of Experimental Medicine, Sapienza University of Rome, ItalyCopyright © 2023 Harbeck, Kropp and Kreitschmann-Andermahr. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
*Correspondence: Birgit Harbeck, b.harbeck@web.de
†These authors share senior authorship